Literature DB >> 19725815

Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes.

Naoko Endo1, Satoshi Kato, Kensuke Haruyama, Munenori Shoji, Shigehiko Kitano.   

Abstract

PURPOSE: To compare the efficacy of bromfenac sodium ophthalmic solution (BF) and a steroidal solution (ST) administered prophylactically against cystoid macular oedema and anterior-chamber inflammation after phacoemulsification and intraocular lens implantation and to assess macular thickness changes using optical coherence tomography (OCT).
METHODS: In this prospective study, 62 eyes of 62 patients were randomized to either the BF group (n=31) or the ST group (n =31). The average perifoveal thickness (AFT) was measured by OCT preoperatively, and 1 day and 1, 2, 4 and 6 weeks postoperatively. The best-corrected visual acuity, intraocular pressure and flare in the anterior chamber were recorded at each visit. The same method was used to compare patients with non-proliferative diabetic retinopathy (NPDR) in the BF (n = 16) and ST (n =11) groups.
RESULTS: In the analysis of all patients, flare in the anterior chamber was significantly (p = 0.007) lower in the BF group 2 weeks postoperatively. In patients with NPDR, the anterior chamber flare values were significantly lower in the BF group at 4 weeks (p = 0.0009) and 6 weeks (p = 0.005). The AFT values were significantly lower in the BF group at 4 weeks (p < 0.0001) and 6 weeks (p < 0.0001). No adverse events occurred in either group.
CONCLUSION: BF suppressed anterior chamber inflammation and increasing retinal thickening after cataract surgery in patients with NPDR.
© 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19725815     DOI: 10.1111/j.1755-3768.2009.01582.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  19 in total

1.  Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial.

Authors:  Masoud Soheilian; Saeed Karimi; Alireza Ramezani; Talieh Montahai; Mehdi Yaseri; Roham Soheilian; Gholam A Peyman
Journal:  Int Ophthalmol       Date:  2014-07-19       Impact factor: 2.031

2.  Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs and corticosteroid drugs for prevention of cystoid macular edema after cataract surgery.

Authors:  Shan-Shan Li; Hui-Hui Wang; Yan-Ling Wang; Da-Wei Zhang; Xi Chen
Journal:  Int Ophthalmol       Date:  2022-09-06       Impact factor: 2.029

3.  Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Heshmatollah Ghanbari; Farzan Kianersi; Seyed Ali Sonbolestan; Mohammad-Ali Abtahi; Mojataba Akbari; Zahra-Alsadat Abtahi; Seyed-Hossein Abtahi
Journal:  Int Ophthalmol       Date:  2016-09-13       Impact factor: 2.031

4.  Uveitic Macular Edema: Treatment Update.

Authors:  Raquel Goldhardt; Bradley Simon Rosen
Journal:  Curr Ophthalmol Rep       Date:  2016-02-18

Review 5.  Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.

Authors:  Viral V Juthani; Elizabeth Clearfield; Roy S Chuck
Journal:  Cochrane Database Syst Rev       Date:  2017-07-03

6.  Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema.

Authors:  Alaa E Radwan; Cheryl A Arcinue; Paul Yang; Pichaporn Artornsombudh; Esam M Abu Al-Fadl; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-22       Impact factor: 3.117

Review 7.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

Review 8.  Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.

Authors:  Winfried M Amoaku; Faruque Ghanchi; Clare Bailey; Sanjiv Banerjee; Somnath Banerjee; Louise Downey; Richard Gale; Robin Hamilton; Kamlesh Khunti; Esther Posner; Fahd Quhill; Stephen Robinson; Roopa Setty; Dawn Sim; Deepali Varma; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-06       Impact factor: 3.775

9.  Cataract and diabetic retinopathy.

Authors:  James Rice
Journal:  Community Eye Health       Date:  2011-09

Review 10.  Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence.

Authors:  Rajesh K Rajpal; Bryan Ross; Sachin D Rajpal; Khoa Hoang
Journal:  Patient Prefer Adherence       Date:  2014-06-25       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.